A Houston researcher is at the center of a global push to turn a weight-loss and diabetes drug into a simple once-a-day pill. A newly published, Houston-led clinical trial reports that a daily oral GLP‑1 pill delivered measurable weight loss and better blood‑sugar control in adults with type 2 diabetes and obesity. The 72‑week ATTAIN‑2 study, led by Dr. Deborah Horn of UTHealth Houston, showed dose‑dependent results, with many participants on the highest dose hitting double‑digit weight reductions, as reported by Newswise.
According to a press release from UTHealth Houston on Newswise, ATTAIN‑2 enrolled 1,613 adults across 136 sites in 10 countries. Participants started at 1 mg and were escalated to maintenance doses of 6 mg, 12 mg, or 36 mg. After 72 weeks, average body‑weight reductions hit 5.5% (6 mg), 7.8% (12 mg), and 10.5% (36 mg), compared with 2.2% for those on placebo, and investigators reported improvements in blood‑sugar measures. The release also notes that the full manuscript was published today in The Lancet.
ATTAIN‑2 Results: Weight Loss And Glycemic Gains
Weight loss was only part of the story. Investigators also reported clinically meaningful drops in A1c and better cardiometabolic markers, signaling tighter diabetes control alongside slimmer waistlines. Medscape summarized that orforglipron lowered average A1c levels and boosted the share of participants who met standard diabetes‑control thresholds at higher doses.
On the flip side, the safety profile looked familiar to anyone who has followed GLP‑1 drugs. Trial data showed mostly mild to moderate gastrointestinal issues, with nausea, diarrhea, and constipation leading the complaint list. Those problems drove higher discontinuation rates at the larger doses, according to a safety summary from Drugs.com.
Why An Oral GLP‑1 Pill Could Expand Access
Orforglipron is a small‑molecule, nonpeptide GLP‑1 receptor agonist taken once daily, and it skips some of the hassles that come with injectables. It does not require refrigeration or tight rules about timing doses around meals, which could make life easier for patients juggling jobs, families, and multiple prescriptions.
In the UTHealth materials, Dr. Horn described the drug as one that “could position it to be the 'metformin' of obesity,” capturing hopes that a pill could be easier and cheaper to scale than today’s injectable GLP‑1 drugs. The Newswise release also notes that orforglipron can be taken without food or water restrictions.
Regulatory Timeline And What To Expect
Drugmaker Eli Lilly is not hiding its urgency. Medscape reports that company sources expect to file for obesity approvals around the world by the end of 2025, with type 2 diabetes submissions following in 2026. If regulators sign off, Horn and other experts say orforglipron could reach clinics as soon as 2026, though real‑world factors such as price, insurance coverage, and how well patients tolerate the drug will ultimately decide how widely it is used.
What Clinicians And Patients Should Watch For
Specialists are cautiously optimistic but hardly ready to declare victory. They point out that switching from injections to a pill does not answer the big open questions: long‑term safety, how this oral option stacks up against established injectables, and whether health plans will pay for it.
Earlier phase research published in the New England Journal of Medicine found double‑digit mean weight loss at the highest doses in adults without diabetes, but clinicians say head‑to‑head trials and insurance coverage decisions will ultimately shape who can access the drug after any approval. For practical safety considerations, Drugs.com highlights gastrointestinal side effects as the most common problems and outlines how frequently patients discontinued at different doses.
Together, UTHealth’s press materials and the published ATTAIN‑2 trial offer regulators and front‑line clinicians the data they will lean on as approval decisions move forward. Patients who are curious about where this pill might fit into their own treatment options and timelines are urged to talk with their health care providers for personalized advice.
